# Cell Press Response Letter — Examples and Best Practices

> 审稿回复信实例与最佳实践

---

## 完整回复信示例 | Full Response Letter Example

### Decision Letter Context

```
Manuscript: Cell-D-24-01234
Title: "Single-Cell Multi-Omics Reveals a Novel Regulatory Circuit in
       Human Neural Development"
Decision: Major Revision
Timeline: 3 months
```

---

### Response to Editor

```markdown
Dear Dr. Thompson,

Thank you for the opportunity to revise our manuscript entitled
"Single-Cell Multi-Omics Reveals a Novel Regulatory Circuit in Human
Neural Development" (Cell-D-24-01234). We are grateful for the thorough
and constructive reviews, which have helped us significantly strengthen
the paper.

We have carefully addressed all concerns raised by the reviewers and
the editorial team. The major revisions include:

1. We have performed new CRISPRi validation experiments targeting the
   three key transcription factors (new Figure 5 and Figure S5).
2. We have expanded the donor cohort from n=3 to n=8 for the single-cell
   analysis (revised Figure 1 and Figure S1).
3. We have added a comprehensive statistical analysis section and power
   calculations (revised STAR Methods).
4. We have included a new "Limitations of the Study" section as
   recommended.

All changes in the revised manuscript are highlighted in blue text.
Below, we provide detailed point-by-point responses to each comment.

Sincerely,
Dr. Jane Smith
On behalf of all authors
```

---

### Response to Reviewer 1

```markdown
## Response to Reviewer 1

**Reviewer 1, Comment 1 (Major):**
**"The authors claim to identify a novel regulatory circuit, but the
functional validation is limited to correlation-based evidence. The
manuscript would be substantially strengthened by perturbation
experiments (e.g., CRISPRi/CRISPRa) to demonstrate causality."**

We thank the reviewer for this important suggestion. We agree that
functional validation is essential to support our claims of a causal
regulatory circuit.

We have now performed CRISPRi experiments targeting the three key
transcription factors (SOX2, NEUROD1, and POU3F2) individually and in
combination in human iPSC-derived neural progenitor cells. The results
demonstrate:

1. Individual knockdown of SOX2 disrupted progenitor maintenance
   (Figure 5A-B)
2. NEUROD1 knockdown blocked neuronal differentiation (Figure 5C-D)
3. Combined perturbation of the circuit abolished the transition
   phenotype (Figure 5E-F)
4. Transcriptomic analysis of perturbed cells confirmed the predicted
   downstream targets (Figure S5A-D)

These new data are presented in new Figure 5 and Supplemental Figure S5.
The Results section has been updated (page 12, lines 287-321):

> "To functionally validate the identified regulatory circuit, we
> performed CRISPRi-mediated knockdown of SOX2, NEUROD1, and POU3F2
> in iPSC-derived neural progenitor cells..."

---

**Reviewer 1, Comment 2 (Minor):**
**"The sample size (n=3 donors) is relatively small for drawing
conclusions about human neural development. Can the authors increase
the cohort or provide power calculations?"**

We appreciate this concern about statistical robustness. We have now:

1. Expanded our donor cohort from n=3 to n=8 donors (5 additional
   donors processed and sequenced)
2. Performed formal power calculations demonstrating adequate statistical
   power for detecting the reported differences
3. Confirmed all major findings are reproducible across the expanded
   cohort (revised Figure 1B, Figure S1A-C)

The STAR Methods section has been updated with detailed power analysis
(page 24, lines 562-578).

---

**Reviewer 1, Comment 3 (Minor):**
**"The writing in the Discussion could be more balanced regarding
alternative interpretations of the data."**

We agree that a more balanced discussion strengthens the manuscript.
We have revised the Discussion to explicitly address alternative
interpretations:

1. The possibility that the circuit operates differently in vivo vs.
   in vitro (page 15, lines 356-362)
2. Potential confounding effects of culture conditions (page 15,
   lines 363-370)
3. Alternative regulatory mechanisms that may act in parallel
   (page 16, lines 371-380)

---
```

### Response to Reviewer 2

```markdown
## Response to Reviewer 2

**Reviewer 2, Comment 1 (Major):**
**"I am not convinced that the computational trajectory analysis
accurately reflects true developmental time. The authors should
validate their trajectory with RNA velocity or lineage tracing."**

We thank the reviewer for this insightful suggestion. We have now
performed RNA velocity analysis using scVelo (Bergen et al., 2020),
which independently confirms our trajectory ordering:

1. RNA velocity vectors align with the inferred pseudotime trajectory
   (new Figure S2A)
2. The transition point identified by velocity analysis coincides with
   our computationally predicted bifurcation (Figure S2B)
3. Latent time estimates from the dynamical model are highly correlated
   with our pseudotime (R = 0.89, p < 1e-10; Figure S2C)

While in vivo lineage tracing would provide the gold standard
validation, we note that this is technically challenging in human
developing brain tissue. We have acknowledged this limitation in the
new "Limitations of the Study" section (page 17, lines 401-406).

---

**Reviewer 2, Comment 2 (Minor):**
**"The Key Resources Table is incomplete — several antibodies used in
immunofluorescence are not listed."**

We apologize for this oversight. We have updated the Key Resources Table
to include all antibodies used in the study, with complete catalog
numbers and RRIDs:

- Anti-SOX2 (Abcam, Cat# ab97959; RRID:AB_2341193)
- Anti-NEUROD1 (Cell Signaling, Cat# 4373; RRID:AB_2149157)
- Anti-POU3F2 (Santa Cruz, Cat# sc-393324; RRID:AB_2737347)
- Anti-MAP2 (Sigma, Cat# M4403; RRID:AB_477193)
- Anti-NESTIN (Millipore, Cat# MAB5326; RRID:AB_2251134)

---

**Reviewer 2, Comment 3 (Suggestion):**
**"It would be interesting to compare these findings with non-human
primate data to assess evolutionary conservation."**

We thank the reviewer for this interesting suggestion. While a
comprehensive cross-species comparison is beyond the scope of the
current study, we have:

1. Added a brief comparison with publicly available macaque data
   (Zhu et al., 2023) showing conservation of 2/3 circuit components
   (new Figure S6)
2. Discussed evolutionary implications in the revised Discussion
   (page 16, lines 382-390)
3. Proposed this as a key future direction

We believe a full cross-species multi-omics study would constitute
a separate investigation and hope the reviewer finds our current
addition satisfactory.
```

---

## 常见审稿意见类型与回复模板 | Common Comment Types

### Type 1: 要求新实验

**Reviewer 写法：** "The authors should perform..."

**回复策略：**
- 如果可行：执行并展示结果
- 如果不可行：解释原因 + 替代方案
- 如果超出范围：礼貌说明 + 加入讨论

### Type 2: 质疑统计方法

**Reviewer 写法：** "The statistical analysis is inadequate..."

**回复策略：**
- 补充统计细节到 QUANTIFICATION AND STATISTICAL ANALYSIS
- 增加 power analysis
- 考虑替代统计方法并比较结果

### Type 3: 要求引用特定论文

**Reviewer 写法：** "The authors should cite..."

**回复策略：**
- 如果相关：添加引用并说明
- 如果是 reviewer 自引：仍然添加（除非完全不相关）
- 格式："We thank the reviewer for pointing us to this relevant work. We have now cited [Author et al., Year] in the revised Introduction (page X, line XX)."

### Type 4: 文字/表述问题

**Reviewer 写法：** "The writing is unclear in..."

**回复策略：**
- 直接修改并引用新文字
- 不要辩解原来的表述已经很清楚

### Type 5: 质疑结论强度

**Reviewer 写法：** "The conclusions are overstated..."

**回复策略：**
- 修改语气（"demonstrate" → "suggest"）
- 添加适当的 hedging language
- 在 Limitations 中承认

---

## 禁忌用语 | Phrases to Avoid

| ❌ 不要写 | ✅ 改为 |
|-----------|---------|
| "The reviewer failed to notice..." | "We apologize for the unclear presentation. We have now..." |
| "This was clearly stated..." | "We have now made this point more explicit by..." |
| "We disagree." | "We respectfully offer an alternative interpretation..." |
| "This is beyond the scope." (alone) | "While this is an interesting direction, it would constitute a separate study. We have discussed it as a future direction..." |
| "As we said in the paper..." | "We appreciate the opportunity to clarify this point..." |

---

## 回复信格式规范 | Formatting Standards

1. **字体**: Times New Roman 11pt 或 Arial 11pt
2. **Reviewer 意见**: 加粗或斜体
3. **回复内容**: 正常字体
4. **引用修改稿文字**: 缩进块引用
5. **新图引用**: "(new Figure X)" 或 "(revised Figure X)"
6. **页码引用**: "(page X, lines XX-XX)"
7. **分隔符**: 每条意见之间用水平线分隔
8. **编号系统**: "Reviewer 1, Comment 1" 或 "R1C1"

---

## 时间线管理 | Timeline Tips

| 阶段 | 建议时间 |
|------|---------|
| 分析意见 + 制定策略 | 1-2 天 |
| 实验/分析工作 | 视需求，不超过 deadline |
| 撰写回复信 | 3-5 天 |
| 修改稿件 | 同步进行 |
| 内部审查 | 2-3 天（让共同作者审阅） |
| 最终提交 | 留 3-5 天余量 |
